Research
Hormonal
GLP-1 receptor agonists and GIP may influence cardiac lipid metabolism by modulating LPL activity, potentially offering cardioprotection, though the specific effect on cardiac LPL remains unclear.
GLP-1 and GIP drugs help with weight and glucose, but they may also directly affect how the heart processes fat. The exact impact on the heart is still being studied, but it may offer additional protection beyond weight loss.
LimitedConditionalLOW confidence
Given the opposing mechanisms of LPL regulation between adipose tissue and the heart, it is possible that GIP lowers cardiac LPL activity. Interestingly, eliminating GIP receptor signaling protected the heart against experimental myocardial infarction, and this was associated with reduced phosphorylation of HSL and increased cardiac TG storage [126].
Why this rating
Based on animal models and in vitro studies; human clinical outcomes are mentioned but mechanisms are 'not completely understood'.
Source
Lipoprotein lipase as a target for obesity/diabetes related cardiovascular disease
Rui Shang et al. · Journal of Pharmacy & Pharmaceutical Sciences · 2024
DOI 10.3389/jpps.2024.13199
narrative_reviewCited 18×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In severe diabetes, reduced cardiac lipoprotein lipase (LPL) activity forces cardiomyocytes to rely on non-esterified fatty acids (NEFA) from adipose tissue, causing mitochondrial overload, lipid metabolite accumulation, and cardiac lipotoxicity.Moderate
- Macrophage-specific lipoprotein lipase (LPL) promotes atherosclerosis by acting as a bridging molecule for remnant lipoprotein uptake, leading to foam cell formation and plaque progression.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →